📰 Objective Response News
Objective Response News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Objective Response. Real-time updates on events, politics, business and more.
October 23, 2023
Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer established a favorable safety profile and...
March 13, 2023
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
December 9, 2022
/PRNewswire/ -- Syntrix Pharmaceuticals today announced results from a single-arm, open-label Phase 1 trial of single-agent SX-682, an investigational CXCR1/2...
November 7, 2022
07.11.2022 - Results show strong signals of clinical responses in patients with advanced cervical cancer who received up to 2 prior lines of therapyOSLO, Norway, Nov. 07, 2022 (GLOBE NEWSWIRE) - Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage ... Seite 1
September 11, 2022
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced detailed results from the global Phase 3 CodeBreaK 200 trial, which showed once-daily oral...
December 2, 2021
02.12.2021 - IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and blood cancers, today announced new translational data implicating B cells in the ... Seite 1
July 16, 2021
EQS-Adhoc: Polyphor AG: Polyphor gibt Update zur Zukunft der FORTRESS-Studie mit Balixafortide und kündigt erste Restrukturierungsschritte an Polyphor gibt Update zur Zukunft der FORTRESS-Studie mit Balixafortide und kündigt erste Restrukturierungsschritte an 16.07.2021 / 07:30 CET/CEST Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Allschwil, Schweiz, 16. Juli 2021 Polyphor gibt Update zur Zukunft de...
May 10, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation. DOORwaY-90 study for SIR-Spheres® therapy as first-line treatment for hepatocellular carcinoma enrolls first patient May 10, 2021 GMT Sirtex DOORwaY-90 Study Logo First prospective multicenter U.S.-based trial for indication expansion of SIR-Spheres® Y-90 resin microspheres taking place in 15 sites across the U.S. WOBURN, Mass., May 10, 2021 /PRNewswire/ -- Sirtex Medical (“Sirtex”), a leading manu...